[Reuters] – Biogen Idec on Monday reported $286 million in third-quarter sales of its high-profile new multiple sclerosis drug Tecfidera, providing fresh evidence that the medicine is off to an impressive launch and . . . → Read More: Market Update on Biogen Idec Inc. (NASDAQ:BIIB) – Biogen’s new MS drug tops sales expectations, earnings rise Similar posts: Johnson & Johnson (NYSE:JNJ) – U.S. guidelines expand potential uses of J&J TB drug [Reuters] – New federal guidelines expand the range of... 3M Company (NYSE:MMM) – 3M Co profit rises 6 pct as sales grow [Reuters] – 3M Co reported a 6 percent rise... Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review [Reuters] – A new hepatitis C drug made by...
[Reuters] – Biogen Idec on Monday reported $286 million in third-quarter sales of its high-profile new multiple sclerosis drug Tecfidera, providing fresh evidence that the medicine is off to an impressive launch and …
Read more on this.
Biogen Idec Inc. (BIIB), valued at $60.30B, opened this morning at … [visit site to read more]
Similar posts:- Johnson & Johnson (NYSE:JNJ) – U.S. guidelines expand potential uses of J&J TB drug [Reuters] – New federal guidelines expand the range of...
- 3M Company (NYSE:MMM) – 3M Co profit rises 6 pct as sales grow [Reuters] – 3M Co reported a 6 percent rise...
- Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review [Reuters] – A new hepatitis C drug made by...
